Ann: Conclusion of Genentech Antimicrobial Collaboration, page-8

Not according to my broker unless they are accelerating the other programs. He says the main expense now sits in Vision Pharma and is funded. PYCTx is left with $15m cash including rebate Currently due which is enough to fund 2 years of an expanded PTCTx model into the US.

He reckons it is magical - both Vision and PYCTx get multiple R&D rebates so the $30m across the companies provides something like $40-50m in funding.

Also said a bunch of instos were closed out of this raise because they were too slow (Australian, Asian and Middle Eastern - also have US based funds interested if they get BIGGER - says their minimum investments are USD10-25m each)

he likens it to the path Avita took and says the valuation ’could’ go to 300-500m within 6 months. He reckons if they get to 500m-1b they ‘should’ raise USD100-200m and accelerate 4-5 more programs and says there are already investors that ’could’ fund it.

I have to say i listened with pretty heavy scepticism and it hasn't made me buy any but he tells a great story!

i think he knows i am looking again and is trying to get me excited again.